azithromycin SR (Zithromax; compound: CP-62,993) + levofloxacin
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Maxillary Sinusitis
Conditions
Maxillary Sinusitis
Trial Timeline
Jan 1, 2003 → Feb 1, 2004
NCT ID
NCT00643409About azithromycin SR (Zithromax; compound: CP-62,993) + levofloxacin
azithromycin SR (Zithromax; compound: CP-62,993) + levofloxacin is a phase 3 stage product being developed by Pfizer for Maxillary Sinusitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00643409. Target conditions include Maxillary Sinusitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00643409 | Phase 3 | Completed |
| NCT00644449 | Phase 3 | Completed |
Competing Products
5 competing products in Maxillary Sinusitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| levofloxacin | Johnson & Johnson | Phase 3 | 77 |
| Azithromycin SR + Amoxiclav 1000 mg | Pfizer | Pre-clinical | 22 |
| Telithromycin | Sanofi | Phase 3 | 76 |
| Azithromycin + Telithromycin | Sanofi | Approved | 84 |
| Avelox (Moxifloxacin, BAY12-8039) | Bayer | Approved | 82 |